MC10 Announces the Use of BioStamp nPoint® in Phase III Study of Huntington Disease
(WorldNews Business)

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 13, 2019-- MC10, Inc., the developer of BioStamp nPoint ®, an end-to-end system for physiological data collection and analytics, announced today that the BioStamp nPoint system will be utilized to collect and assess movement activity data in a new Phase III study evaluating a potential treatment for chorea associated with Huntington disease, a hereditary neurodegenerative disease. The study is sponsored by Neurocrine Biosciences and conducted in collaboration with the Huntington Study...